Longevica operates an open research tool and dataset that tracks the effects of more than 1,000 pharmacological compounds to accelerate testing of longevity hypotheses. The company is also commercializing consumer products and in April launched a line of supplements derived from its research. Its internal study tested 1,033 compounds and showed significant life‑extension properties; the company is close to publishing a peer‑reviewed paper on that work. Longevica plans to test 300 of those compounds in a new study at Jackson Laboratory and will open applications in January for researchers to participate in a full‑scale pharmacological screening experiment beginning June 2022. The platform and database will be free and open source, with marked‑up mouse longevity experiment data and program code published on GitHub. Longevica got its start more than 11 years ago and is led by co‑founder and CEO Ainar Abdrakhmanov alongside co‑founder Dr. Alexey Ryazanov. Longevica is a longevity biotech that spent 11 years researching supplements and building a biotechnology platform based on long‑lived mouse studies. The platform is based on work by scientist Alexey Ryazanov, who holds 10 U.S. patents in the field. Using 20,000 long‑lived female mice and a screen of 1,033 drugs from 62 pharmacological classes, the company identified five substances that increased lifespan by 16–22%: Inulin, Pentetic Acid, Clofibrate, Proscillaridin A and D‑Valine. Longevica says it will produce medicines, dietary supplements and food products and plans to launch its supplements later this year. The company has attracted investor capital and positions its products against a rapidly growing market for older adults, a point emphasized by CEO Ainar Abdrakhmanov.

Total raised

$16M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2021